Achieving secondary prevention low-density lipoprotein particle concentration goals using lipoprotein cholesterol-based data

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Mathews, Simon C ^a   Mallidi, Jaya ^b,c   Kulkarni, Krishnaji ^d   Toth, Peter P ^e,f   Jones, Steven R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c BAYSTATE MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e CGH MEDICAL CENTER   (United States)

^f UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOTYPE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SECONDARY PREVENTION; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION;

AGED; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT CARE PLANNING; PERIPHERAL VASCULAR DISEASES; ROC CURVE; SECONDARY PREVENTION;

EID: 84859065879     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033692     Document Type: Article

References (32)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106: 3143-3421.
2. Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, et al. (2007) LDL particle number and risk of future cardiovascular disease in the framingham offspring study- implications for LDL management. J Clin Lipidol 1: 583-592.
3. El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, et al. (2007) Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: The EPIC-norfolk prospective population study. J Am Coll Cardiol 49: 547-553.
4. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, et al. (2006) Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial. Circulation 113: 1556-1563.
5. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, et al. (2009) Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 119: 931-939.
6. Kuller L, Arnold A, Tracy R, Otvos JD, Burke G, et al. (2002) Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 22: 1175-1180.
7. Blake GJ, Otvos JD, Rifai N, Ridker PM, (2002) Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106: 1930-1937.
8. Rosenson RS, Otvos JD, Freedman DS, (2002) Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trial. Am J Cardiol 90: 89-94.
9. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, et al. (2009) Apolipoprotein B and cardiovascular disease risk: Position statement from the AACC lipoproteins and vascular diseases division working group on best practices. Clin Chem 55: 407-419.
10. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, et al. (2006) Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirty-person/ten-country panel. J Intern Med 259: 247-258.
11. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, et al. (2008) Lipoprotein management in patients with cardiometabolic risk: Consensus conference report from the american diabetes association and the american college of cardiology foundation. J Am Coll Cardiol 51: 1512-1524.
12. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, et al. (2004) Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110: 227-239.
13. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, et al. (2007) LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 192: 211-217.
14. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, et al. (2003) Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139: 802-809.
15. Boizel R, Benhamou PY, Lardy B, Laporte F, Foulon T, et al. (2000) Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care 23: 1679-1685.
16. Kulkarni KR, Garber DW, Marcovina SM, Segrest JP, (1994) Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res 35: 159-168.
17. Kulkarni KR, (2006) Cholesterol profile measurement by vertical auto profile method. Clin Lab Med 26: 787-802.
18. Otvos JD, (2002) Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48: 171-180.
19. Otvos JD, Jeyarajah EJ, Cromwell WC, (2002) Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 90: 22i-29i.
20. Jeyarajah EJ, Cromwell WC, Otvos JD, (2006) Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 26: 847-870.
21. Cromwell WC, Barringer TA, (2009) Low-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease. Curr Cardiol Rep 11: 468-475.
22. Cromwell WC, Otvos JD, (2006) Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am J Cardiol 98: 1599-1602.
23. Sniderman A, (2008) Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: Implications for clinical practice. J Clin Lipidol 2: 36-42.
24. Nielsen LB, (1996) Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis 123: 1-15.
25. Tabas I, Williams KJ, Boren J, (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications. Circulation 116: 1832-1844.
26. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R, (2004) Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normal. J Am Coll Cardiol 43: 2142-2146.
27. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504.
28. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425-1435.
29. McPherson R, Frohlich J, Fodor G, Genest J, (2006) Canadian cardiovascular society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 22: 913-927.
30. Gardner CD, Fortmann SP, Krauss RM, (1996) Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276: 875-881.
31. Lamarche B, St-Pierre AC, Ruel IL, Cantin B, Dagenais GR, et al. (2001) A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol 17: 859-865.
32. St-Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, et al. (2005) Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the quebec cardiovascular study. Arterioscler Thromb Vasc Biol 25: 553-559.